Ara A Kardashian, Paul J Pockros
Dr Kardashian is a fellow in the Division of Gastroenterology and Hepatology at Scripps Clinic in La Jolla, California. Dr Pockros is the director of the Liver Disease Center at Scripps Clinic and is the director of clinical research at Scripps Translational Science Institute in La Jolla, California.
Gastroenterol Hepatol (N Y). 2015 Jul;11(7):458-66.
The treatment of hepatitis C virus infection has been advancing at breakneck speeds over the past few years. This article provides an update on the newest drugs available and those currently in development, including newer-generation protease inhibitors, RNA-dependent RNA polymerase, and nonstructural component inhibitors. Also discussed in this article are the regimens developed and the genotypes they target. Treatment of cirrhotic patients and patients who have failed prior therapy is also addressed, as are special populations, such as patients with harder-to-treat genotypes, patients with HIV coinfection, patients who have undergone liver transplantation, and patients with chronic kidney disease. Future developments and economic considerations are also mentioned.
在过去几年中，丙型肝炎病毒感染的治疗进展极其迅速。本文提供了有关现有最新药物以及目前正在研发的药物的最新信息，包括新一代蛋白酶抑制剂、RNA依赖性RNA聚合酶和非结构成分抑制剂。本文还讨论了已制定的治疗方案及其针对的基因型。同时也探讨了肝硬化患者以及先前治疗失败患者的治疗方法，以及特殊人群，如基因型较难治疗的患者、合并感染HIV的患者、接受过肝移植的患者和患有慢性肾病的患者。此外，还提到了未来的发展和经济考量。
